SGLT2 inhibitors and GLP-1 receptor agonists now have well-established cardiovascular and renal benefits. What does this mean for their role in the management of type 2 diabetes? Justin Coleman chats with endocrinologist and clinical pharmacologist, Tilenka Thynne, about this and other updates to Therapeutic Guidelines Diabetes.